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Abstract The pulmonary circulation, at the unique
crossroads between the left and the right heart, is submitted
to large physiologic hemodynamic variations and possesses
numerous important metabolic functions mediated through
its vast endothelial surface. There are many pathologic
conditions that can directly or indirectly affect the pul-
monary vasculature and modify its physiology and func-
tions. Pulmonary hypertension, the end result of many of
these affections, is unfortunately diagnosed too late in the
disease process, meaning that there is a crying need for
earlier diagnosis and surrogate markers of disease pro-
gression and regression. By targeting endothelial, medial
and adventitial targets of the pulmonary vasculature, novel
molecular imaging agents could provide early detection of
physiologic and biologic perturbation in the pulmonary
circulation. This review provides the rationale for the
development of molecular imaging agents for the diagnosis
and follow-up of disorders of the pulmonary circulation
and discusses promising targets for SPECT and positron
emission tomographic imaging.
Keywords Molecular imaging  Lung remodeling 
Endothelium  Fibrosis  Apoptosis  Proliferation
Introduction
With the exception of labeled macroaggregates of albumin
(MAA), used almost exclusively for the diagnosis of pul-
monary embolism, there is currently no radionuclide agent
routinely employed to study the pulmonary circulation in
humans. Positioned at the unique crossroads between the
right and the left heart, the pulmonary circulation is sub-
mitted to large physiologic hemodynamic variations serv-
ing gas exchanges. Furthermore, the pulmonary vascular
endothelium represents a vast surface area responsible for
numerous important metabolic functions affecting systemic
functions. Many pathologic conditions directly or indi-
rectly affect the pulmonary circulation and modify
molecular pathways contained within the different layers of
the pulmonary vasculature: the endothelium, media and
adventitia. In this review, we discuss the opportunities and
challenges involved in developing molecular imaging
agents for detecting normal physiologic variations and
pathologic disorders affecting the pulmonary circulation.
Anatomy and physiology of the pulmonary circulation
The pulmonary circulation serves its primary function of
gas exchange through a very large capillary surface area.
By virtue of its great capacitance and low resistance, it is
able to accommodate sizeable physiologic variations of the
cardiac output with little variation in mean pulmonary
artery pressure. This unique capacity is in part due to the
postural perfusion gradient resulting from the gravity-
dependent interplay between the alveolar pressure and the
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pulmonary capillary pressure in different regions of the
lungs. Therefore gravity and other factors, to be detailed
later, result in uneven spatial distribution of pulmonary
perfusion.
With increases in pulmonary blood flow, such as during
exercise, lung vascular recruitment occurs in the less
dependent regions of the lungs leading to modification of
the spatial distribution of blood flow. In diseases causing a
progressive loss of pulmonary microcirculation, such as
pulmonary hypertension (PH), the impact of this loss on the
spatial distribution of pulmonary perfusion is currently
uncertain. Therefore, this parameter is not clinically uti-
lized to detect and monitor disease progression.
The first studies describing the heterogeneity of lung
perfusion led to the ‘‘zone model’’ of lung perfusion
developed by West et al. [1, 2]. This classical physiologic
model, still taught today, relies principally on the gravita-
tional gradient to describe four zones of perfusion, in the
upright posture, from the apex to the base of the lungs. This
model, resulting from the interplay between arteriolar,
venular and alveolar pressures, depicts increasing perfusion
from the apex to the base of the lungs except in zone 4,
where it was postulated that compression of extra-alveolar
vessels results in decreasing perfusion [3] (Fig. 1). Since
then, numerous studies have confirmed a gravitational lung
perfusion gradient in upright, supine and prone positions in
man as well as in quadrupeds [4–10]. Besides the effect of
gravity on perfusion pressure, the so called ‘‘slinky’’ effect
also contributes to greater perfusion in the most dependent
regions of the lungs as gravity causes tissue compression
and greater lung parenchymal density [5].
However, factors other than gravity also contribute to
the heterogeneity of lung perfusion, and the question of
whether gravity is the principal determinant of the spatial
distribution of lung perfusion has been the subject of much
heated debate [11–15]. There is indeed evidence of per-
fusion heterogeneity even in isogravitational planes. Hakim
et al. [4, 16] demonstrated a decreasing centro-peripheral
perfusion gradient in isogravitational planes of human and
canine lungs and hypothesized that this observation resul-
ted from varying regional vascular conductance at
branching points. Indeed, studies performed in micro-
gravity environments revealed that some lung perfusion
heterogeneity persisted [17]. A novel fractal model incor-
porating isogravitational heterogeneity was proposed by
Glenny et al. [18–20], who suggested that as the spatial
resolution of the instruments of measure is improved, iso-
gravitational perfusion heterogeneity is revealed [11]
(Fig. 1).
Although the relative importance of the determinants of
the spatial distribution of pulmonary perfusion is the sub-
ject of an ongoing debate, there is consensus on its ultimate
finality. The heterogeneity of lung perfusion confers great
capacitance on the pulmonary vasculature and the possi-
bility to increase (recruit) tissue perfusion for gas
exchanges in response to increasing cardiac output. Using
the multiple indicator-dilution technique in exercising
dogs, we demonstrated that the metabolically active pul-
monary vascular surface area increased almost linearly
with tripling of blood flow [21–23]. Furthermore, lung
vascular recruitment continues to occur even after full lung
tissue recruitment measured from the tracer-accessible
Fig. 1 Blood flow as a function of height up the lung in an upright
primate. Data are from 1,265 pieces of lung (2 cm3 in volume) and
were obtained using the microsphere method. Left data averaged
within horizontal planes to reproduce the spatial resolution available
at the time the gravitational model was conceptualized. Right same
data but at a resolution that permits the heterogeneity of perfusion to
be observed. At the lower spatial resolution, the data are remarkably
similar to those of the zone model described by Hughes and West [1–
3] and gravity appears to be a major determinant of perfusion
(r2 = 0.640). However, at the higher resolution, gravity can account
for at most 28 % of the variability in perfusion. Reproduced with
permission from the Journal of Applied Physiology: Glenny [11]
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extravascular lung water [21–23]. There is therefore a
pulmonary vascular ‘‘reserve’’ that can accommodate the
increase in cardiac output and expand the surface available
for gas exchanges and pulmonary metabolic functions.
Lung vascular recruitment in response to increasing blood
flow will accordingly modify the spatial distribution of
pulmonary perfusion with a reduction in the gravitational
gradient component [9, 10, 24]. Study of the spatial dis-
tribution of the metabolically active pulmonary circulation
at rest and with increasing pulmonary blood flow, such as
exercise, could therefore provide a unique insight into the
capacity of the lung to recruit vascular surface area. More
importantly, study of the spatial distribution of perfusion in
conditions associated with a loss of recruitable pulmonary
perfusion, such as PH, could provide a unique method for
detecting disease earlier than is currently possible.
The difficulty and importance of early detection
of pulmonary vascular disease
Pulmonary hypertension (PH) results from various clinical
conditions and is defined as a mean pulmonary artery
pressure C25 mmHg at rest. The pathophysiology-based
classification of PH comprises five groups [25] (Table 1).
Although not the most prevalent form, Group 1 PH is
attracting increasing attention, with novel selective phar-
macologic therapies having been developed and approved
in the past 10 years. Group 1 PH, often referred to as
pulmonary arterial hypertension (PAH), is a severe angio-
proliferative disease of the pulmonary microcirculation
which causes progressive obliteration of distal pulmonary
arteries measuring less than 500 lm. It may be idiopathic,
hereditary or linked to various disorders such as collagen
vascular diseases, portal hypertension, congenital heart
disease, HIV infection, drugs and toxins, schistosomiasis
and others [25].
Despite modern diagnostic modalities, more than
2 years will typically elapse between initial medical con-
tact and the diagnosis of group 1 PH [26–28]. At the time
of diagnosis, up to 75 % of subjects are already in NYHA
functional class III or IV [26]. Although specific PAH
therapies are available, the prognosis of this condition
remains exceedingly poor. In the REVEAL study registry,
the one-, three-, five- and seven-year survival rates from
time of diagnosis were 85, 68, 57 and 49 %, respectively,
in patients with all-cause PAH [29]. For patients with idi-
opathic PAH, heritable PAH or drug-induced PAH, the
three-year survival was 58.2 %. There is clearly an urgent
need for earlier detection of pulmonary vascular disease
[30, 31].
Other groups of PH, such as PH due to left heart disease
(group 2) and PH due to lung parenchymal disease (group
3) are much more prevalent and confer a very poor prog-
nosis in affected subjects. Unfortunately, there are no
specific therapies currently approved for these groups of
PH and evidence-based guidelines for a diagnostic and
monitoring imaging approach are lacking.
The main reason for the delay in the diagnosis of PH
resides in the recruitable pulmonary vascular reserve: it is
estimated that more than 50 % of the pulmonary vascular
bed is obliterated before there is a detectable rise in mean
resting pulmonary artery pressure [30]. Indeed, normal
subjects can withstand a unilateral pneumonectomy with-
out significant hemodynamic PH in the remaining lung [32,
33]. Some advocate the measurement of pulmonary artery
pressure at exercise to allow earlier detection of PH.
Although pulmonary artery systolic pressure can be non-





1.2.2.ALK-1, ENG, SMAD9, CAV1, KCNK3 mutations
1.2.3.Unknown







10 Pulmonary veno-occlusive disease and/or pulmonary capillary
hemangiomatosis
100 Persistent pulmonary hypertension of the newborn (PPHN)
2.Pulmonary hypertension due to left heart disease
2.1.Left ventricular systolic dysfunction
2.2.Left ventricular diastolic dysfunction
2.3.Valvular disease
2.4.Congenital/acquired left heart inflow/outflow tract obstruction
and congenital cardiomyopathies
3.Pulmonary hypertension due to lung diseases and/or hypoxia
3.1.Chronic obstructive pulmonary disease
3.2.Interstitial lung disease




3.6.Chronic exposure to high altitude
3.7.Developmental lung diseases
4.Chronic thromboembolic pulmonary hypertension (CTEPH)
5.Pulmonary hypertension with unclear multifactorial mechanisms
Classification from the proceedings of the 5th World Symposium on
PH [100]
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invasively measured during exercise with echocardiogra-
phy, the approach is currently debated due to the lack of a
specific upper-bound estimate and is not recommended as a
screening test for PH [34, 35]. Because of the recruitable
vascular reserve, the pressure rise in PH is a late event.
Thus, there is a need for methods allowing earlier direct
assessment the status of the pulmonary circulation. As
novel pharmacologic agents continue to be developed,
earlier diagnosis and therapy may have greater benefits on
morbidity and mortality. Evaluation of the spatial distri-
bution of pulmonary perfusion at rest and during exercise
may provide an earlier and sensitive insight into the status
of the pulmonary circulation. Modification of the spatial
distribution of lung perfusion may be detectable well
before a significant rise in resting pulmonary artery
pressure.
Molecular imaging agents targeting the pulmonary cir-
culation therefore hold promise as sensitive early indicators
of pulmonary vascular disease and of its progression or
regression. Currently, the diagnosis of PH (Table 1)
requires an invasive right heart catheterization and there is
no consensus on what non-invasive clinical parameter is
the best surrogate marker of severity and prognosis.
Metabolic functions of the pulmonary vascular
endothelium
The pulmonary circulation has numerous important meta-
bolic functions exerted through its specialized capillary
endothelial cells [36]: it produces, activates, modifies and
degrades circulating mediators affecting not only the
underlying smooth muscle cells but also the systemic cir-
culation and organs. Endothelial functions of potential
interest for molecular imaging are depicted in Fig. 2.
Endothelial dysfunction is an early event in pulmonary
vascular disease and many endothelial functions are
potential targets for molecular imaging. Prototypical tar-
gets include the angiotensin-converting enzyme (ACE),
serotonin (5-HT) and norepinephrine (NE) transporters,
endothelin production and clearance, and finally the pro-
duction of the endothelium-derived relaxing factor nitric
oxide (NO). ACE is an ectoenzyme located at the luminal
surface of the pulmonary vascular endothelium, responsi-
ble for converting angiotensin I into angiotensin II, a potent
systemic vasoconstrictor. The pulmonary circulation is the
major site of ACE activity and radiolabeled ACE substrates
have been used to measure lung capillary recruitment with
increasing pulmonary blood flow [22, 37]. By contrast,
serotonin and NE are removed from circulation by the
lungs [38]. Lung uptake of 14C-serotonin and 3H-NE have
been used to demonstrate lung vascular recruitment and the
increase in metabolically active pulmonary vascular
surface with exercise [21, 23]. The pulmonary vascular
endothelium is an important site of production and clear-
ance of circulating endothelin 1 (ET-1), a potent vaso-
constrictor and proliferator implicated in the
pathophysiology of PH. Production of both endothelial
prostacycline (PGI2) and NO is reduced in PAH and related
to increased vascular tone and an increased proliferative
profile of the endothelium and vascular smooth muscle
cells.
It is generally recognized that endothelial dysfunction is
an early initiating event in the development of group I PH
and contributes to the abnormal pulmonary vascular reac-
tivity and remodeling of all PH groups. Endothelial meta-
bolic functions are therefore putative molecular imaging
targets for monitoring disorders affecting the pulmonary
circulation. Furthermore, increased endothelial cell apop-
tosis associated with quasi-clonal proliferation of activated
apoptotic-resistant endothelial cells is a hallmark of PAH,
which is characterized by activation of these respective
biologic pathways [39].
Molecular imaging of the pulmonary vasculature
Many molecular imaging agents have demonstrated lung
uptake and potential utility in the diagnosis of pulmonary
vascular disease. Table 2 lists some of these agents and
their molecular targets. However, very few have been
tested in human subjects. This is by no means an exhaus-
tive list as agents developed for other purposes may also
allow pulmonary vascular imaging, even though they were
not specifically evaluated for this purpose. We here review
and discuss in greater detail some agents of interest that
have more specifically been tested as agents for the eval-
uation of PH.
Endothelium
Various molecular tracers targeting the pulmonary vascular
endothelium have been tested in pre-clinical studies
although few have been evaluated in humans. Here we
discuss four endothelial metabolic functions that have been
explored in some detail for their potential clinical rele-
vance: the adrenomedullin (AM) receptor, the endothelin-B
receptor (ETB), ACE and the NE transporter.
Human AM, a member of the calcitonin gene-related
peptide family, is a 52-amino-acid multifunctional regula-
tory peptide expressed in a wide range of tissues but mainly
in the adrenal medulla, ventricle, kidneys and lungs [40–
42]. Its specific heterodimeric receptor is composed of the
calcitonin-like receptor and the receptor activity-modifying
protein 2 or 3 [43]. The AM receptor is abundantly
expressed in human alveolar capillaries and mostly
418 Clin Transl Imaging (2014) 2:415–426
123
distributed at the luminal surface of the vascular endothe-
lium [44–47]. Accordingly, the lungs contain specific AM-
binding sites at a density higher than any other organ
studied [47]. We have previously established that the lungs
are a primary site for plasma AM clearance and therefore
modulate its circulating levels [48]. In fact, the AM receptor
acts as a clearance receptor in the pulmonary vascular bed
[49]. On the basis of this evidence, we hypothesized that
radiolabeled AM derivatives could be used as non-invasive
imaging tracers to evaluate the integrity of the pulmonary
circulation. Through rational design and structure–activity
relationship studies we developed various AM derivatives
[50] able to maintain binding affinity with the specific
receptor without significant biologic effects at the lung scan
dose, while enabling the addition of a chelating moiety for a
suitable radioisotope [51]. These derivatives allowed good
quality lung imaging enabling the detection of large pul-
monary perfusion defects mimicking pulmonary embolism
[52], but also microcirculatory pulmonary occlusion in the
monocrotaline model of PAH [53] (Fig. 3). A lead com-
pound possessing the desired properties was selected [51]
and called PulmoBind. In pre-clinical studies, 99mTc-Pul-
moBind displays all the qualities desired of a molecular
imaging agent in nuclear medicine: sizeable first pass and
prolonged uptake by the lungs and quick plasma clearance
with elimination by both the liver and kidneys [51]. A
human phase I study of PulmoBind in normal human sub-
jects was recently completed (Clinicaltrials.gov
NCT01539889) [54]. We demonstrated that PulmoBind is
safe while providing superior quality lung imaging com-
pared to 99mTc-MAA. A phase II study of safety and proof
of concept in subjects with PAH is in the planning phase.
We hypothesize that quantitative total lung uptake and
kinetic parameters after PulmoBind injection will be of
value in the evaluation of all the PH groups (Table 1).
Furthermore, evaluation of the spatial distribution of Pul-
moBind uptake may provide a unique insight into modifi-
cations of the metabolically active pulmonary vascular
surface area in both physiology and pathology.
Endothelin-1 (ET-1) is a potent vasoconstrictor and
proliferator peptide produced by the vascular endothelium.
The ET system is activated in and contributes to all groups
of PH. ET exerts its biologic effects mainly by acting on
two receptor sub-types: ETA and ETB [55, 56]. While ETA
is expressed only on smooth muscle cells, ETB is expressed
both on smooth muscle cells and on the endothelium [57].
The endothelial ETB is densely expressed in the pulmonary
circulation that acts as a clearance site for circulating ET-1
[58]. Using the indicator-dilution technique in man,
approximately 47 % of circulating ET-1 is cleared by the
Fig. 2 Biologic functions of the endothelial and muscular layers of the
pulmonary vasculature. Various mediators are produced, transformed or
inactivated by the pulmonary vascular endothelial cells. Specific receptors
and transporters are expressed by endothelial and vascular smooth muscle
cells. Nitric oxide (NO); endothelium-derived hyperpolarizing factor
(EDHF); prostacyclin (PGI2); angiotensin-converting enzyme (ACE);
acetylcholine (Ach); angiotensin I (AI); angiotensin II (AII); angiotensin 1
receptor (AT1); bradykinin (Bk); cyclo-oxygenase (COX); endothelin-
converting enzyme (ECE); endothelin A and B receptors (ETA, ETB);
endothelin-1 (ET-1); L-arginine (L-Arg); prostaglandin H2 (PGH2);
reactive oxygen species (ROS); serotoninergic receptor (S1); thrombox-
ane receptor (TH); thrombin (Thr); thromboxane A2 (TXA2); serotonin
(5-HT); opioid receptor (OR); calcitonin receptor-like receptor-receptor
activity modifying protein (CRLR-RAMP); adrenomedullin (AM);
neurokinin receptor (NK-1); substance P (SP); vasoactive intestinal
peptide receptor (VPAC); vasoactive intestinal peptide (VIP); aminopep-
tidase P (AP-P); norepinephrine transporter (NET); norepinephrine (NE);
serotonin transporter (5-HTT) (color figure online)
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lungs during a single circulatory transit time [59, 60].
Furthermore, clearance seemed to be differently affected
by the various PH groups: it was reduced in group 2 PH but
surprisingly preserved in some subjects with group 1 PH
and chronic thromboembolic PH (group 4) [61]. Pulmonary
clearance of ET-1 was reduced in patients with systolic
heart failure (group 2 PH) in relation to the severity of PH
[62]. In vivo imaging of the pulmonary endothelial ETB
receptor was performed by Davenport using 18F-ET-1 and
the radiolabeled selective ETB antagonist
18F-BQ-3020
[63, 64]. In animal studies, using a micro-PET, these
tracers were rapidly and substantially taken up by the
pulmonary circulation, resulting in good lung imaging. The
specific role of the endothelial ETB was confirmed by the
inhibition of lung uptake after the administration of another
selective ETB antagonist. Unfortunately no further explo-
rations with these tracers have been performed in pul-
monary vascular disorders or in human subjects.
Angiotensin-converting enzyme (ACE) is an ectoen-
zyme located at the luminal surface of the pulmonary
vascular endothelium and it is responsible for the hydro-
lysis of angiotensin I into the potent vasoconstrictor/pro-
liferator angiotensin II (Ang-II). The lungs are the main
site of circulating Ang-II production. Various ACE sub-
strates and antagonists have been developed and labeled to
study pulmonary ACE activity in vivo. Using the indicator-
dilution approach, ACE substrates have been validated as
tools for studying the metabolically active pulmonary
vascular surface area in animals [22, 37] and in humans
[65]. Pulmonary endothelial ACE activity is reduced by
acute vascular lung injury and in subjects with PH [66, 67].
ACE inhibitors are among the most widely prescribed
cardiovascular drugs and molecular lung imaging has been
performed in humans using 18F-fluorocaptopril and 18F-
lisinopril. Lung ACE imaging was performed in human
subjects with 18F-fluorocaptopril and a three-compartment
model was used to estimate total ACE binding [68]. The
authors found marked reduction of ACE binding in subjects
with PAH and could image and quantify the pharmacologic
efficacy of ACE antagonists.
Table 2 Molecular PET and SPECT radioligands used to image the pulmonary vasculature
Target Radioligand
Opioid receptor 3H-fentanyl [101], 11C-MeJDTic [102]
Adrenomedullin receptor 99mTc-AM-L [53], 99mTc-PulmoBind [51]
Beta-adrenoreceptor 3H-propranolol [103], 14C-propranolol [104, 105]
Serotonin receptor 11C-GSK215083 [106]
Dopamine receptor 11C-NNC 112 [107]
Endothelin ET(B) receptor 18F-BQ3020 [64]
Neurokinin NK-1 receptor 18F-SPA-RQ [108]
Vasoactive intestinal peptide receptor 123I -VIP [109, 110]
Glucagon-like peptide-1 receptor [Lys(40)(Ahx-DOTA-(68)Ga)NH(2)]-exendin-4 [111, 112]
Norepinephrine transporter 123I-MIBG [70–72, 113–115]
Serotonin transporter 123I-ADAM [116, 117], 11C-DASB [118], 14C-serotonin [103],
123I-FP-CIT [119, 120]
123I-iodoamphetamine [121], 123I-HIPDM [122]
Glucose transporter 18F-FDG [79–81]
MMPs, gelatinase 99mTc-DTPA-CLP [123], 99mTc-CTT [124]
Aminopeptidase P 125I-833c [125], 99mTc-mAPP [126]
Externalized phosphatidylserine 99mTc-annexin V [76–78]
Angiotensin-converting enzyme 3H-BPAP [65, 66], 11C-zofenoprilat [127], 18F-fluorocaptopril [68],
99mTc-lisinopril [128]
11 C-MeJDTic = 11C–N-methylated derivative of JDTic ((3R)-7-hydroxy-N-[(2S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl]-3-methylbutan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide); 11C-NNC 112 = 11C((?)-8-chloro-5-(7-benzofuranyl)-7-hydroxy-3-
methyl-2,3,4,5-tetrahydro-1H-3-benzazepine); 18F-BQ3020 = 18F-([Ala11,15]Ac-ET-1(6–21)); 18F-SPA-RQ = 18F-[2-fluoromethoxy-5-(5-tri-
fluoromethyl-tetrazol-1-yl)-benzyl]-[(2S,3S)-2-phenyl-piperidin-3-yl)amine]; 123I-MIBG = 123I-metaiodobenzyl guanidine; 123I-ADAM = 123I-
2-((2-((dimethylamino)methyl) phenyl)thio)-5-iodophenylamine; 11C-DASB = 11C-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl) ben-
zonitrile; 123I-FP-CIT: 123I-N-x-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) nortropane; 123I-iodoamphetamine = 123I-N-isopropyl
p-iodoamphetamine; 123I-HIPDM = 123I-N,N,N0-trimethyl-N-(2-hydroxy-3-methyl-5 iodobenzyl)-1, 3 propanediamine; 18F-FDG: 18F-fluoro-2-
deoxy-2-D-glucose; 99mTc-DTPA-CLP = 99mTc-DTPA-Cys-Leu-Pro-Gly-His-Trp-Gly-Phe-Pro-Ser-Cys; 99mTc-CTT = 99mTc-Cys-Thr-Thr-
His-Trp-Gly-Phe-Thr-Leu-Cys; 125I-833c = 125I- radiolabeled aminopeptidase P-specific recombinant antibody; 99mTc-mAPP = 99mTc-radio-
labeled monoclonal antibody to aminopeptidase; 3H-BPAP = 3H-benzoyl-phenylalanyl-alanyl-proline; 11C-zofenoprilat = 11C-(4S)-1-[(S)-3-
Mercapto-2-methylpropanoyl]-4-phenylthio-L-proline. AM-L = linear form of human adrenomedullin
420 Clin Transl Imaging (2014) 2:415–426
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The lungs extract circulating NE by a specific trans-
porter located in the vascular endothelium and this biologic
function has been exploited for molecular imaging of the
pulmonary vasculature. This energy-dependent process was
imaged using 123I-metaiodobenzylguanidine (MIBG) scin-
tigraphy, studying the lung uptake and wash-out of the
radioimaging agent [69]. Studies have shown diminished
lung extraction of 123I-MIBG in patients with chronic
obstructive pulmonary disease, pulmonary fibrosis, vascu-
litis, and after radiotherapy and high altitude hypoxia [70–
74]. Despite its potential, this agent is not currently used
for diagnosis of lung vascular disorders. The lung imaging
technique with 123I-MIBG has never been standardized and
the biology of the tracer remains uncertain as lung neuronal
uptake, in addition to endothelial uptake, likely contributes
to the kinetics of this tracer [69].
Apoptosis and proliferation
The pathophysiology of PH is complex and incompletely
understood. It comprises early endothelial injury (dys-
function) with inflammation and dysregulation of growth
factors [75]. This translates into endothelial apoptosis fol-
lowed by proliferation of apoptosis-resistant endothelial
cells and of vascular smooth muscle cells, leading to the
angioproliferative phenotype pathognomonic of group 1
PH (PAH) with the formation of plexiform lesions. Even-
tually, all types of PH will display pulmonary artery
smooth muscle cell proliferation and fibroblast prolifera-
tion with possible obliteration of the vascular lumen.
Annexin V is a ubiquitous protein that binds to phos-
phatidylserine expressed on the surface of apoptotic cells
but also on ‘‘stressed’’ or injured cells [76]. Radiolabeled
annexin V has been used as a cancer imaging agent but also
has potential for a variety of pulmonary pathologies
involving apoptosis and inflammation [76], including PH.
In the monocrotaline model of PAH, 99mTc-annexin V
imaging showed clear increases in pulmonary apoptosis,
which regressed with effective therapy [77]. In a murine
model of acute lung transplant rejection, 99mTc-annexin V
lung uptake was increased in relation to the severity of
histological rejection [78].
The metabolic glycolytic shift of proliferating cells can
be detected using 18F-fluorodeoxy-glucose positron emis-
sion tomography (18F-FDG PET), a technique that is
widely used in oncology. The paradigm of quasi-clonal
proliferation of endothelial cells and vascular smooth
muscle cell proliferation associated with PAH was tested in
animal models and in human studies. In the murine mon-
ocrotaline model as well as in the hypoxia-Sugen model of
PAH there is increased pulmonary 18F-FDG PET uptake,
which occurs early and correlates with disease severity
[79]. Furthermore, it is associated with increased expres-
sion of the GLUT1 transporter in both endothelial cells and
pulmonary vascular smooth muscle cells. Lack of upreg-
ulation of the glucose transporter in inflammatory cells
would suggest, at least in these models, that 18F-FDG PET
can be used to monitor the vascular proliferative compo-
nent of PAH [79]. In human PAH, two small studies
revealed a mean increase of lung parenchymal 18F-FDG
PET activity [80, 81]. The 18F-FDG PET activity was,
however, heterogeneously distributed within the lungs and
showed wide variability between subjects, with some
patients having normal uptake. Although the within-lung
heterogeneity would seem to be consistent with the known
heterogeneity of histological pathology in PAH [75], the
between-subject variability raises the concern that the 18F-
FDG tracer may not gain access to some diseased areas due
to blockade of pulmonary vessels, a problem inherent to a
disease causing a reduction in perfusion. Indeed, and
Fig. 3 Molecular imaging of pulmonary arterial hypertension using
an adrenomedullin receptor ligand. Images obtained 30 min after an
i.v. injection of 99mTc-PulmoBind in a vehicle-treated Sprague–
Dawley rat and b monocrotaline-treated rat (pulmonary arterial
hypertension model). c Static evaluations of the presence of the
radiotracer in lungs 30 and 60 min after injection. *p \ 0.05 for
vehicle-treated rats (white bars) versus monocrotaline-treated rats
(black bars). This research was originally published in the Journal of
Nuclear Medicine: Letourneau et al., PulmoBind an adrenomedullin-
based molecular lung imaging tool, 2013; vol. 54, 1789–1796.  by
the Society of Nuclear Medicine and Molecular Imaging, Inc. [51]
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contrary to cancer in which proliferating tumors are gen-
erally highly vascularized, PH causes a reduction in per-
fusion that is proportional to the disease severity. Another
limitation of 18F-FDG PET is its lack of specificity for the
lung vasculature. Indeed, other lung conditions such as
pulmonary fibrosis and diseases causing parenchymal lung
damage are associated with increased 18F-FDG PET
activity in regions of fibrosis [82].
Agents used to measure pulmonary perfusion
Both particulate and non-particulate agents have been used
to measure pulmonary perfusion. Although some are not
molecular imaging agents per se, they are nevertheless here
reviewed briefly.
Non-particulate agents that cross the alveolar blood-
gas barrier may be used to measure pulmonary perfu-
sion. Initially, radiolabeled carbon dioxide (C15O2) was
used by inhalation in combination with detection sys-
tems using external scintigraphic probes. This allowed
approximate measurement of regional pulmonary per-
fusion [1, 2, 83]. 133Xenon, previously used to quantify
cerebral perfusion, has also been evaluated for pul-
monary applications after first being dissolved in phys-
iologic saline for intravenous injection [84, 85]. The
introduction of planar detection systems (Anger Cam-
era) has enabled the creation of images showing the
distribution of pulmonary perfusion.
The method most frequently used for the measurement
of pulmonary perfusion involves the injection of radiola-
beled particles that lodge in the pulmonary vasculature
through microembolization [86]. Depending on their size,
these particles lodge in the smallest vessels they can
reach. The MAA constitute the prototype of those sub-
stances [87–89]. These radiopharmaceuticals were found
to be well suited to new technological developments in
detection systems. Indeed, the addition of a tomographic
camera (SPECT) has allowed the creation of three-
dimensional images. The longer time required to obtain
these images from the SPECT camera precluded the use
of non-particulate radiopharmaceuticals. Therefore, MAA
were used after labeling with 99mtechnetium or
113mIndium [90, 91]. Many studies have been conducted
using this tracer and the 99mTc-MAA are still widely used
in clinical applications. Some groups have also used
81mkrypton [92]. However, this radioisotope, with a very
short half-life (13 s), required continuous infusion in order
to create scintigraphic images. Although more accurate,
the SPECT technique does not allow absolute quantitative
analysis.
The introduction of the positron emission tomographic
camera (PET scanner) as an absolute measuring system has
driven the development and use of new
radiopharmaceuticals. This camera includes an efficient
attenuation correction system and is able to provide
quantitative data on the biodistribution of radiotracers
injected into patients. These tracers must be positron
emitters. Of these, some, such as 13N2, have been used to
measure pulmonary perfusion. 13N2 is not very soluble and
when dissolved in saline, and after intravenous injection, it
rapidly diffuses into the alveolar space during the lung’s
first-pass transit [93–96]. The tracer travels preferentially
into the active alveoli, i.e. alveoli perfused by functional
pulmonary capillaries. Thus, the tracer uptake in the lungs
is a real marker of pulmonary perfusion. Oxygen-15
(H2
15O) has also been used [97–99]. Again, this very short-
life radiotracer must be injected according to a constant
infusion model. Moreover, the biodistribution of the tracer
needs to be measured and these calculations require the use
of compartmental analysis. Finally, positron-emitting par-
ticulate tracers have been developed for the quantification
of pulmonary perfusion, including 68Ga-labeled MAA.
Conclusions
There are numerous clinical disorders that can directly
or indirectly impact the pulmonary circulation leading
to the development of PH. Unfortunately, there is cur-
rently no non-invasive diagnostic modality that can
provide direct information on the pathophysiologic
processes affecting the different layers of the pulmonary
vasculature: the endothelium, the media and the
adventitia. Molecular imaging using innovative SPECT
and PET radiotracers offers promising prospects for the
evaluation of the pulmonary circulation in physiologic
and pathologic conditions. More importantly, molecular
imaging could provide earlier detection of the disease,
prior to the development of overt hemodynamic PH.
Endothelial dysfunction is an early event in the devel-
opment of PH and, in this regard, the authors believe the
most promising agents will target endothelial metabolic
properties. Some promising studies have been per-
formed with agents targeting the endothelin receptors,
the ACE, the NE transporter and more recently the AM
receptor. The latter is to be tested in an upcoming phase
II study. The future of molecular imaging of the pul-
monary circulation in health and disease is promising.
We predict that multimodality imaging with SPECT/CT
and PET/MRI will provide combined anatomical and
functional information essential to diagnosis, follow-up
and therapeutic decisions in this field.
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